Symbols / PCSA Stock $2.85 -4.52% Processa Pharmaceuticals, Inc.

Healthcare • Biotechnology • United States • NCM
PCSA (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. George K. Ng Esq., J.D.
Exch · Country NCM · United States
Market Cap 7.58M
Enterprise Value 2.40M
Income -13.56M
Sales —
FCF (ttm) -6.55M
Book/sh 2.17
Cash/sh 2.08
Employees 12
Insider 10d —
IPO Mar 07, 2014
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -0.76
PEG —
P/S —
P/B 1.31
P/C —
EV/EBITDA -0.17
EV/Sales —
Quick Ratio 2.48
Current Ratio 2.54
Debt/Eq —
LT Debt/Eq —
EPS (ttm) -10.36
EPS next Y -3.75
EPS Growth —
Revenue Growth —
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2025-11-06
Earnings (prior) 2025-11-06
ROA -158.34%
ROE -3.73%
ROIC —
Gross Margin 0.00%
Oper. Margin 0.00%
Profit Margin 0.00%
Shs Outstand 2.66M
Shs Float 2.41M
Insider Own 13.35%
Instit Own 8.31%
Short Float 3.94%
Short Ratio 1.70
Short Interest 103.92K
52W High 19.62
vs 52W High -85.48%
52W Low 1.76
vs 52W Low 61.93%
Beta 0.89
Impl. Vol. —
Rel Volume 0.40
Avg Volume 55.91K
Volume 22.27K
Target (mean) —
Tgt Median —
Tgt Low —
Tgt High —
# Analysts —
Recom None
Prev Close $2.98
Price $2.85
Change -4.52%
About

Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells. Its oncology pipeline includes NGC-Cap (PCS6422), a combination of PCS6422 and capecitabine, which is in a Phase 2 clinical trial to treat metastatic breast, colorectal, hepatocellular, pancreatic, gastric, and other solid tumors; and NGC-Iri (PCS11T), an analog of an active metabolite of irinotecan, which is in preclinical trials to treat lung, pancreatic, ovarian, colorectal, gastric, cervical, and other cancers. The company also develops non-oncology drugs consisting of PCS499, an oral tablet of the deuterated analog of pentoxifylline that has completed a Phase 2b clinical trial for the treatment of primary glomerular diseases, including focal segmental glomerulosclerosis (FSGS), IgA, and membranous nephropathy, as well as ulcerative necrobiosis lipoidica; and PCS12852, a highly specific and potent 5HT4 agonist that has completed a Phase 2 clinical trial for the treatment of gastroparesis and constipation disorders. It has license agreements with Elion Oncology, Inc., Aposense, Ltd., Yuhan Corporation, and Sun Pharmaceuticals Industries Limited. Processa Pharmaceuticals, Inc. was founded in 2015 and is based in Vero Beach, Florida.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$2.85
Latest analyst target
3. DCF / Fair value
$-44.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.85
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-09-02 main HC Wainwright & Co. Buy → Buy $1
2025-06-30 main HC Wainwright & Co. Buy → Buy $2
2024-12-05 reit HC Wainwright & Co. Buy → Buy $6
2024-08-20 reit HC Wainwright & Co. Buy → Buy $6
2024-08-19 main HC Wainwright & Co. Buy → Buy $6
2024-08-01 reit HC Wainwright & Co. Buy → Buy $8
2024-06-12 reit HC Wainwright & Co. Buy → Buy $8
2024-05-13 reit HC Wainwright & Co. Buy → Buy $8
2024-04-25 init HC Wainwright & Co. — → Buy $8
2024-03-06 reit Benchmark Speculative Buy → Speculative Buy $4
News
RSS: Latest PCSA news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-15 SKIBSTED RUSSELL L Chief Financial Officer — 1,984 $2.97 $5,892
2026-04-15 YOUNG DAVID Officer and Director — 1,545 $2.97 $4,589
2026-04-15 NG GEORGE K Chief Executive Officer — 1,843 $2.97 $5,474
2026-04-15 LIN PATRICK Officer — 1,369 $2.97 $4,066
2026-04-15 BIGORA SIAN Officer — 1,799 $2.97 $5,343
2026-04-15 GUY WENDY Officer — 1,583 $2.97 $4,702
2026-03-31 NEAL JAMES R Director — 789 $2.54 $2,000
2026-03-31 SKIBSTED RUSSELL L Chief Financial Officer — 2,324 $2.54 $5,891
2026-03-31 YOUNG DAVID Officer and Director — 1,810 $2.54 $4,588
2026-03-31 NG GEORGE K Chief Executive Officer — 2,136 $2.54 $5,415
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
13.99
+16.08%
12.05
+5.19%
11.46
-43.44%
20.26
Research And Development
7.81
+7.45%
7.27
+25.34%
5.80
-49.54%
11.49
Selling General And Administration
6.18
+29.19%
4.78
-15.47%
5.66
-35.44%
8.76
General And Administrative Expense
6.18
+29.19%
4.78
-15.47%
5.66
-35.44%
8.76
Other Gand A
6.18
+29.19%
4.78
-15.47%
5.66
-35.44%
8.76
Total Expenses
13.99
+16.08%
12.05
+5.19%
11.46
-43.44%
20.26
Operating Income
-13.99
-16.08%
-12.05
-5.19%
-11.46
+43.44%
-20.26
Total Operating Income As Reported
-13.99
-16.08%
-12.05
-5.19%
-11.46
+58.38%
-27.53
EBITDA
-13.99
-16.07%
-12.05
-5.18%
-11.46
+41.15%
-19.47
Normalized EBITDA
-14.28
-18.52%
-12.05
-5.18%
-11.46
+6.10%
-12.20
Reconciled Depreciation
0.00
+53.96%
0.00
+252.25%
0.00
-99.97%
0.79
EBIT
-13.99
-16.08%
-12.05
-5.19%
-11.46
+43.44%
-20.26
Total Unusual Items
0.30
—
0.00
+100.00%
-7.27
Total Unusual Items Excluding Goodwill
0.30
—
0.00
+100.00%
-7.27
Special Income Charges
—
—
0.00
+100.00%
-7.27
Other Special Charges
—
—
—
—
Impairment Of Capital Assets
—
—
0.00
-100.00%
7.27
Net Income
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Pretax Income
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Net Non Operating Interest Income Expense
0.11
-45.55%
0.20
-40.07%
0.34
+231.56%
0.10
Interest Expense Non Operating
—
—
—
—
Net Interest Income
0.11
-45.55%
0.20
-40.07%
0.34
+231.56%
0.10
Interest Expense
—
—
—
—
Interest Income Non Operating
0.11
-45.55%
0.20
-40.07%
0.34
+231.56%
0.10
Interest Income
0.11
-45.55%
0.20
-40.07%
0.34
+231.56%
0.10
Other Income Expense
0.32
—
—
-7.27
Other Non Operating Income Expenses
0.02
—
—
—
Gain On Sale Of Security
0.30
—
—
—
Tax Provision
0.00
—
0.00
0.00
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Net Income From Continuing Operation Net Minority Interest
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Net Income From Continuing And Discontinued Operation
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Net Income Continuous Operations
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Normalized Income
-13.86
-16.95%
-11.85
-6.55%
-11.12
+44.82%
-20.16
Net Income Common Stockholders
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Otherunder Preferred Stock Dividend
—
—
—
—
Diluted EPS
—
-96.78
+54.35%
-212.00
+75.10%
-851.25
Basic EPS
—
-96.78
+54.35%
-212.00
+75.10%
-851.25
Basic Average Shares
—
0.12
+133.38%
0.05
+62.83%
0.03
Diluted Average Shares
—
0.12
+133.38%
0.05
+62.83%
0.03
Diluted NI Availto Com Stockholders
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
7.81
+141.96%
3.23
-44.19%
5.79
-32.87%
8.62
Current Assets
5.67
+201.78%
1.88
-66.64%
5.63
-32.84%
8.39
Cash Cash Equivalents And Short Term Investments
5.54
+364.77%
1.19
-74.69%
4.71
-27.64%
6.50
Cash And Cash Equivalents
5.54
+364.77%
1.19
-74.69%
4.71
-27.64%
6.50
Receivables
—
—
—
0.00
Taxes Receivable
—
—
—
0.00
Prepaid Assets
—
—
—
1.88
Other Current Assets
0.13
-80.53%
0.69
-25.74%
0.93
-50.81%
1.88
Total Non Current Assets
2.14
+58.70%
1.35
+775.88%
0.15
-33.88%
0.23
Net PPE
0.00
-94.96%
0.08
-49.07%
0.15
-34.70%
0.23
Gross PPE
0.00
-94.96%
0.08
-49.07%
0.15
-34.70%
0.23
Accumulated Depreciation
—
—
—
—
Machinery Furniture Equipment
—
—
—
—
Other Properties
0.00
-94.96%
0.08
-49.07%
0.15
-34.70%
0.23
Goodwill And Other Intangible Assets
—
—
0.00
0.00
Other Intangible Assets
—
—
—
—
Non Current Prepaid Assets
0.99
-22.03%
1.27
0.00
—
Other Non Current Assets
1.15
+20589.79%
0.01
+0.00%
0.01
+0.00%
0.01
Total Liabilities Net Minority Interest
2.24
+45.86%
1.53
+92.24%
0.80
-30.60%
1.15
Current Liabilities
2.24
+45.91%
1.53
+109.78%
0.73
-26.84%
1.00
Payables And Accrued Expenses
2.24
+53.21%
1.46
+125.62%
0.65
-29.66%
0.92
Payables
1.06
+19.97%
0.88
+75.95%
0.50
-3.09%
0.52
Accounts Payable
1.06
+19.97%
0.88
+182.68%
0.31
-4.86%
0.33
Other Payable
—
—
0.19
+0.00%
0.19
Current Accrued Expenses
1.18
+103.80%
0.58
+295.65%
0.15
-63.71%
0.40
Current Debt And Capital Lease Obligation
—
0.07
-12.71%
0.08
+6.02%
0.08
Current Capital Lease Obligation
0.00
-100.00%
0.07
-12.71%
0.08
+6.02%
0.08
Total Non Current Liabilities Net Minority Interest
0.00
-100.00%
0.00
-99.27%
0.07
-55.56%
0.15
Long Term Debt And Capital Lease Obligation
0.00
-100.00%
0.00
-99.27%
0.07
-55.56%
0.15
Long Term Capital Lease Obligation
0.00
-100.00%
0.00
-99.27%
0.07
-55.56%
0.15
Tradeand Other Payables Non Current
—
—
—
—
Non Current Deferred Liabilities
—
—
—
—
Non Current Deferred Taxes Liabilities
—
—
—
—
Stockholders Equity
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Common Stock Equity
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Capital Stock
0.00
+1613.33%
0.00
-88.37%
0.00
+61.25%
0.00
Common Stock
0.00
+1613.33%
0.00
-88.37%
0.00
+61.25%
0.00
Preferred Stock
0.00
0.00
—
—
Share Issued
2.57
+1634.34%
0.15
+187.19%
0.05
+60.02%
0.03
Ordinary Shares Number
2.57
+1636.55%
0.15
+187.92%
0.05
+60.40%
0.03
Treasury Shares Number
0.00
+0.00%
0.00
+0.00%
0.00
+0.00%
0.00
Additional Paid In Capital
106.66
+19.55%
89.22
+10.61%
80.66
+12.00%
72.02
Retained Earnings
-100.78
-15.55%
-87.22
-15.72%
-75.37
-17.31%
-64.25
Treasury Stock
0.30
+0.00%
0.30
+0.00%
0.30
+0.00%
0.30
Total Equity Gross Minority Interest
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Total Capitalization
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Working Capital
3.43
+891.17%
0.35
-92.93%
4.90
-33.65%
7.39
Invested Capital
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Total Debt
0.00
-100.00%
0.07
-51.18%
0.15
-34.38%
0.23
Capital Lease Obligations
0.00
-100.00%
0.07
-51.18%
0.15
-34.38%
0.23
Net Tangible Assets
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Tangible Book Value
5.58
+228.82%
1.70
-66.00%
4.99
-33.22%
7.47
Duefrom Related Parties Current
—
—
—
—
Dueto Related Parties Current
—
0.00
-100.00%
0.00
-23.53%
0.00
Interest Payable
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-11.39
-1.25%
-11.25
-39.46%
-8.06
+16.05%
-9.61
Cash Flow From Continuing Operating Activities
-11.39
-1.25%
-11.25
-39.46%
-8.06
+16.05%
-9.61
Net Income From Continuing Operations
-13.56
-14.46%
-11.85
-6.55%
-11.12
+59.45%
-27.42
Depreciation Amortization Depletion
0.00
+53.96%
0.00
+252.25%
0.00
-99.97%
0.79
Depreciation
0.00
+53.96%
0.00
+252.25%
0.00
0.00
Amortization Cash Flow
—
—
0.00
-100.00%
0.79
Depreciation And Amortization
0.00
+53.96%
0.00
+252.25%
0.00
-99.97%
0.79
Amortization Of Intangibles
—
—
0.00
-100.00%
0.79
Other Non Cash Items
0.07
-18.93%
0.09
-93.74%
1.39
+256.91%
0.39
Stock Based Compensation
0.86
+36.22%
0.63
-40.63%
1.06
-87.99%
8.83
Asset Impairment Charge
—
—
0.00
-100.00%
7.27
Deferred Tax
—
—
—
0.00
Deferred Income Tax
—
—
—
0.00
Operating Gains Losses
—
—
—
—
Unrealized Gain Loss On Investment Securities
-0.30
0.00
—
—
Change In Working Capital
1.54
+1473.96%
-0.11
-118.57%
0.61
+11.33%
0.54
Change In Receivables
0.00
+100.00%
-0.00
-225.00%
-0.00
-100.02%
0.07
Change In Prepaid Assets
0.83
+181.00%
-1.03
-207.69%
0.96
+354.45%
0.21
Change In Payables And Accrued Expense
0.78
-22.47%
1.00
+467.31%
-0.27
-177.38%
0.35
Change In Accrued Expense
0.60
+38.91%
0.43
+268.41%
-0.26
-205.33%
0.24
Change In Payable
0.18
-69.10%
0.57
+3673.30%
-0.02
-114.66%
0.11
Change In Account Payable
0.18
-69.10%
0.57
+3673.30%
-0.02
-114.66%
0.11
Change In Other Working Capital
—
—
-0.00
+99.30%
-0.00
Change In Other Current Liabilities
-0.07
+20.02%
-0.08
-6.02%
-0.08
+10.28%
-0.09
Investing Cash Flow
-0.85
-26102.22%
-0.00
-16.86%
-0.00
0.00
Cash Flow From Continuing Investing Activities
-0.85
-26102.22%
-0.00
-16.86%
-0.00
0.00
Net PPE Purchase And Sale
0.00
+100.00%
-0.00
-16.86%
-0.00
0.00
Purchase Of PPE
0.00
+100.00%
-0.00
-16.86%
-0.00
0.00
Capital Expenditure
-0.85
-26102.22%
-0.00
-16.86%
-0.00
—
Net Intangibles Purchase And Sale
-0.85
0.00
—
—
Purchase Of Intangibles
-0.85
0.00
—
—
Financing Cash Flow
16.58
+114.40%
7.73
+23.37%
6.27
+1712.15%
-0.39
Cash Flow From Continuing Financing Activities
16.58
+114.40%
7.73
+23.37%
6.27
+1712.15%
-0.39
Net Issuance Payments Of Debt
-0.01
-26.91%
-0.01
0.00
—
Issuance Of Debt
—
—
—
—
Repayment Of Debt
-0.01
-26.91%
-0.01
0.00
—
Long Term Debt Issuance
—
—
—
—
Long Term Debt Payments
-0.01
-26.91%
-0.01
0.00
—
Net Long Term Debt Issuance
-0.01
-26.91%
-0.01
0.00
—
Short Term Debt Issuance
—
—
—
—
Net Short Term Debt Issuance
—
—
—
—
Net Common Stock Issuance
16.59
+114.11%
7.75
+22.55%
6.32
+1725.71%
-0.39
Common Stock Payments
-0.01
+34.57%
-0.02
0.00
+100.00%
-0.39
Repurchase Of Capital Stock
-0.01
+34.57%
-0.02
0.00
+100.00%
-0.39
Net Other Financing Charges
—
-0.01
+83.77%
-0.05
—
Changes In Cash
4.35
+223.64%
-3.51
-95.55%
-1.80
+82.02%
-9.99
Beginning Cash Position
1.19
-74.69%
4.71
-27.64%
6.50
-60.58%
16.50
End Cash Position
5.54
+364.77%
1.19
-74.69%
4.71
-27.64%
6.50
Free Cash Flow
-12.24
-8.77%
-11.25
-39.45%
-8.07
+16.02%
-9.61
Interest Paid Supplemental Data
0.01
+365.70%
0.00
0.00
0.00
Income Tax Paid Supplemental Data
0.00
0.00
0.00
0.00
Change In Interest Payable
—
—
—
—
Common Stock Issuance
16.60
+113.80%
7.76
+22.80%
6.32
0.00
Issuance Of Capital Stock
16.60
+113.80%
7.76
+22.80%
6.32
0.00
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category